Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
The moderate to high isolation group demonstrated a significantly elevated risk of dementia compared with the low isolation group.
Why it matters
This longitudinal cohort study found that older adults with moderate to high digital isolation had a significantly elevated risk of dementia compared with those with low isolation. The authors suggest promoting digital literacy and access as part of public health strategies aimed at dementia prevention.
-
When an individual with MCI-LB endorsed more clinical features, they typically experienced a faster cognitive decline (ACE-R Score Difference β = -1.1 [-1.7 to -0.5]), specifically when experiencing visual hallucinations (β = -2.1 [-3.5 to -0.8]) or cognitive fluctuations (β = -3.4 [-4.8 to -2.1]).Individuals with MCI-LB typically acquired more clinical features with the passage of time (25.5% [20.0-32.0%] one-year probability), limiting the prognostic utility of baseline-only features.
Why it matters
This study found that people with mild cognitive impairment with Lewy bodies who had more clinical features, especially visual hallucinations and cognitive fluctuations, declined faster. The clinical picture evolves over time, which may help prognosis, but no treatment or cure is tested.
-
Many individuals with advanced dementia die in hospital, despite preferring home death.
Why it matters
This review of 33 papers covering more than 5 million people examined which factors are linked to where people with advanced dementia die, finding that long-term care deaths were relatively common and hospice deaths rarer. It describes patterns of place of death rather than testing any treatment, so it does not show how to cure or prevent dementia.
-
Incentives are a cornerstone of attracting and retaining participants in clinical research studies.1 They serve as compensation for the time and effort individuals dedicate to the research process.1 However, previous randomized clinical trials found incentivizing was not associated with increased rates of clinical trial recruitment.2, 3 Furthermore, the rate participants redeem these incentives can vary considerably.1, 4 Although numerous methods have been used to increase trial recruitment, no studies have been conducted to explore factors associated with incentive redemption, regardless of clinical area.
Why it matters
This study looked at what factors were linked to whether research participants redeemed their study incentives, and found only age mattered. It has no findings about treating, curing, or preventing Alzheimer's disease.
-
TM was associated with higher odds of 30-day readmission (OR = 1.07 [CI: 1.02 to 1.12]) and frequent hospitalizations (OR = 1.10 [CI: 1.06 to 1.14]) compared to MA.
Why it matters
This study found that traditional Medicare was associated with higher odds of 30-day readmission and frequent hospitalizations compared to Medicare Advantage among beneficiaries with Alzheimer's disease and related dementias. Medicare Advantage was associated with lower Hispanic-White and Black-White disparities in frequent hospitalizations compared with traditional Medicare.
-
Four states have clinician reporting mandates, 14 have mandates requiring drivers to self-report dementia diagnoses, and 32 states and the District of Columbia do not have explicit requirements.
Why it matters
This study suggests that state policies requiring clinicians to report dementia diagnoses to the DMV may be linked to more missed or delayed dementia diagnoses in primary care. It does not address treating, curing, or preventing Alzheimer's disease.
-
The average PM2.5 levels in the IHS counties were lower than those in all US counties, while the mean O3 levels in the IHS counties were higher than the US counties.
Why it matters
In a cohort of American Indians aged 55 and older, higher county-level ozone was associated with a higher risk of dementia, while PM2.5 and NO2 were not associated with dementia risk after adjusting for all covariates. This is an observational link between air pollution and dementia risk, so it cannot show that reducing ozone would prevent dementia.
-
54/100
Selected CSF biomarkers at presentation were associated with etiologic diagnoses and treatment responsiveness in patients with heterogeneous causes of RPD.
Why it matters
In 78 patients with rapidly progressive dementia, selected cerebrospinal fluid biomarkers were associated with specific causes and with whether the condition might respond to treatment. This cross-sectional study supports using such markers to improve diagnosis, not to treat or prevent Alzheimer's disease.
-
In peripheral blood, the overall pooled results showed no significant difference in LCN2 across Alzheimer's disease (AD), MCI and control groups.
Why it matters
Pooling population studies, this meta-analysis found no overall difference in blood levels of lipocalin-2 (LCN2), an inflammation-related protein, between people with Alzheimer's, mild cognitive impairment and controls, though serum levels were higher in Alzheimer's. In spinal fluid there was no difference for Alzheimer's or MCI, but levels were raised in vascular dementia. The authors conclude that blood differences between Alzheimer's and controls may depend on the type of sample and on age.
-
An estimated 2 971 449 individuals (mean age, 66.4 years; 95% CI, 64.8-68.2 years) filled prescriptions for OAB medications in 2019; 2 185 214 (73.5%; 95% CI, 62.6%-84.5%) identified as female, 2 326 901 (78.3%; 95% CI, 66.3%-90.3%) self-identified as non-Hispanic White, 260 685 (8.8%; 95% CI, 5.0%-12.5%) identified as non-Hispanic Black, 167 210 (5.6%; 95% CI, 3.1%-8.2%) identified as Hispanic, 158 507 (5.3%; 95% CI, 2.3%-8.4%) identified as non-Hispanic other race, and 58 147 (2.0%; 95% CI, 0.3%-3.6%) identified as non-Hispanic Asian.
Why it matters
This study looked at who filled prescriptions for overactive bladder medications and found that non-Hispanic Black individuals, especially women, were less likely to receive β3-agonist medications than anticholinergics. It does not test any treatment for Alzheimer's disease and provides no information about curing or preventing it.
-
54/100
In-hospital death among nursing home residents with dementia has been associated with poorer quality of end-of-life care.
Why it matters
This review notes that in-hospital death among nursing home residents with dementia is associated with poorer quality of end-of-life care, and that hospital admissions in the last month of life are common. It also reports that an intervention had no significant effect on the proportion of hospital admissions.
-
Conversion rates increased with increasing CDR-SB scores.
Why it matters
This study found that the sum of boxes of the clinical dementia rating scale in predementia or very mild dementia stages highly predicts progression to dementia or reversion to normal cognition. The authors suggest it could be a good candidate for tracing the effectiveness of interventions in people without dementia.
-
We previously developed a novel machine-learning-based brain age model that was sensitive to amyloid.
Why it matters
This study found that a machine-learning brain age model could estimate brain age and that greater brain age was associated with more amyloid and worse cognitive function, and predicted future cognitive worsening. It is a prediction and monitoring tool, not a treatment, cure, or prevention.
-
In comparison with participants living with others and with normal cognition, those adults living alone with cognitive impairment reported a higher percentage of catastrophic health expenditure (19.5% vs. 11.8%, respectively, P < 0.001).
Why it matters
This study found that Chinese adults living alone with cognitive impairment had higher odds of catastrophic health expenditure. It does not test any treatment, cure, or prevention for Alzheimer's disease, and it suggests health care policies should consider these vulnerable adults.
-
We review the epidemiologic data that led to the recommendation to use diastolic hypertension and proteinuria as diagnostic criteria, as their combined presence was associated with an increased risk of fetal death and the birth of small-for-gestational-age neonates.
Why it matters
This review does not report any test of a treatment, cure, or prevention for Alzheimer's disease. It only discusses ideas about the causes of preeclampsia and eclampsia and notes that it is not known whether preeclampsia increases baseline risk.
-
ReDeSign provides dementia training to convenience store workers and contributes to developing an inclusive community for people with dementia.
Why it matters
This is a study protocol for a randomized controlled trial of an online dementia training for 124 convenience store workers in Tokyo, with attitude toward people with dementia as the primary outcome. No results are reported yet, so it cannot show whether the training changes attitudes or behavior.
-
We will evaluate the effectiveness and safety of combined NF-acupuncture therapy, and expect that it will serve as the basis for the use of NF together with acupuncture in the clinical setting.
Why it matters
This is a protocol for a small pilot trial comparing combined acupuncture and neurofeedback with acupuncture alone in mild neurocognitive disorder. No results are reported, so no conclusion can be drawn about improving cognition or preventing dementia.
-
Mortality due to dementia represents a substantial global burden, and is expected to continue to grow into the future as an older, aging population expands globally.
Why it matters
This study estimated that there were 1.62 million deaths globally due to dementia in 2019, with more deaths in women than men. It reports that deaths due to dementia ranked seventh globally and fourth among individuals 70 and older.
-
Mean total BPSD score was 17.66 ± 20.67, and the mean score for family caregiver burden was 9.65 ± 11.12.
Why it matters
This study reports mean total behavioral and psychological symptoms of dementia and family caregiver burden scores. It does not provide information on treating, curing, or preventing Alzheimer's disease.
-
Recently, there has been growing interest in the glymphatic system (the functional waste clearance pathway for the central nervous system and its role in flushing solutes (such as amyloid ß and tau), metabolic, and other cellular waste products in the brain.
Why it matters
This small imaging study of 36 people examined a possible MRI marker of glymphatic activity across cognitively normal, mild cognitive impairment, and Alzheimer's disease groups. It is early biomarker work in a small sample, not evidence about treating, curing or preventing the disease.
-
Given considerable variation in diagnostic and therapeutic practice, there is a need for national guidance on the use of neuroimaging, fluid biomarkers, cognitive testing, follow-up and diagnostic terminology in mild cognitive impairment (MCI).
Why it matters
This consensus report describes mild cognitive impairment as a risk state in which 5-15% of people develop dementia per year, but about 50% remain stable at 5 years and some improve. It discusses diagnosis and terminology, and notes that biomarkers to identify underlying Alzheimer's disease are not available in routine UK clinical practice.
-
Adherence to the Mediterranean-DASH for Neurodegenerative Delay (MIND) diet has previously been associated with cognitive decline and dementia.
Why it matters
This study evaluated whether adherence to the MIND diet is associated with better cognitive function, larger brain volumes, fewer silent brain infarcts, and less cognitive decline. It does not prove that the diet prevents or treats Alzheimer's disease, only that an association was found.
-
54/100
These results suggest that emerging biomarkers in conjunction with core AD markers improve diagnosis of AD, are associated with the conversion from MCI into AD, and predict a faster progression of dementia.
Why it matters
Combining newer CSF markers with core Alzheimer's markers improved accuracy in identifying amyloid PET positivity and some ratios predicted faster conversion from mild cognitive impairment to Alzheimer's. These findings are about improving diagnosis and tracking progression, not about treating, curing, or preventing the disease.
-
Dementia is one of the most common neurological syndromes in the world.
Why it matters
Deep learning applied to clock-drawing tests achieved high accuracy for dementia screening and scoring, which could allow automated assessment where clinical experts are unavailable. This is a screening and scoring tool, not a treatment, cure or prevention for dementia.
-
Medicare beneficiaries with a little or a lot of trouble hearing had 18% (95% confidence interval [CI] odds ratio [OR] = 1.10-1.27) and 25% (95% CI OR = 1.07-1.47) increased odds of reporting greater difficulty with understanding Medicare, respectively, compared with those with no hearing trouble.
Why it matters
This study found that Medicare beneficiaries with hearing trouble had greater difficulty understanding Medicare. It provides no information about treating, curing, or preventing Alzheimer's disease.
From across this topic
10 of the 7,967 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Motor speech signature of behavioral variant frontotemporal dementia: Refining the phenotype
- Depression and frailty in later life: a systematic review
- Dream recall in cognitively healthy older adults: associations with blood p ‐tau217 levels, APOE ε4 carriage, and cognitive decline
- Relationship between falls and stride length variability in senile dementia of the Alzheimer type
- Community based occupational therapy for patients with dementia and their care givers: randomised controlled trial
- Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study
- Depression-an underrecognized target for prevention of dementia in Alzheimer's disease
- Normative data of the Spanish version of the Montreal Cognitive Assessment (MoCA) in older individuals from Peru
- Differential diagnosis and classification of apathy
- A systematic review of reasons for gatekeeping in palliative care research